Clinical Trials Logo
  1. Home
  2. HIV-1 Infections
  3. NCT00799058

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

HIV-1 Infections Clinical Trial

Official title:
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL TO EVALUATE THE SAFETY OF DAPIVIRINE GEL 4759, 0.05% 2.5g AND DAPIVIRINE GEL 4789, 0.05% 2.5g FORMULATIONS AS COMPARED TO THE VAGINAL HEC-BASED UNIVERSAL PLACEBO GEL, 2.5g IN HEALTHY HIV-NEGATIVE WOMEN

Clinical Trial Summary

A double-blind, randomized, placebo-controlled Phase I/II trial to evaluate the safety of dapivirine Gel 4759, 0.05% 2.5 g and dapivirine Gel 4789, 0.05% 2.5 g formulations as compared to the vaginal HEC-based Universal placebo gel, 2.5 g in healthy HIV-negative women

Clinical Trial Description

This was a double-blind, randomized, placebo-controlled trial, to be conducted over 10 months at five research centers in the USA among 180 healthy, sexually active women, to assess the safety and acceptability of dapivirine Gel 4759, 0.05% 2.5 g, and dapivirine Gel 4789, 0.05% 2.5 g, both vaginal microbicides containing dapivirine, compared to the vaginal HEC-based Universal placebo gel, 2.5 g, containing no active ingredient, used once daily for a period of 12 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00799058
Study type Interventional
Source International Partnership for Microbicides, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 6, 2009
Completion date January 8, 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT01013415 - CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients Phase 1
Active, not recruiting NCT02923713 - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV Phase 2
Completed NCT01151319 - Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults Phase 1
Completed NCT01138605 - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV Phase 2
Completed NCT01078233 - Observational Data Analysis in EuroSIDA (MK-0518-058)
Recruiting NCT02593409 - HIV PrEP Priming of Immune Effectors Phase 4
Completed NCT00557245 - Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples Phase 3
Withdrawn NCT00984152 - Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women Phase 3
Completed NCT01159275 - Lopinavir (LPV) Dose Reduction Phase 1/Phase 2
Completed NCT01281813 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Phase 3
Completed NCT01078246 - Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
Active, not recruiting NCT03027297 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Phase 3
Completed NCT01139905 - Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children Phase 2
Completed NCT01033760 - Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) Phase 3
Completed NCT00830804 - Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults Phase 2
Completed NCT01074931 - Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China N/A